Streetbeat News

Price Targets

USB

Morgan Stanley has upgraded U.S. Bancorp (NYSE:USB) from Equal-Weight to Overweight and increased the price target from $54 to $57, indicating a positive outlook for the stock.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 10:57 am

AYI

Acuity Brands, Inc. (NYSE:AYI) is set to release its Q4 earnings on Oct. 1, with expectations of increased earnings per share and revenue compared to last year. Analysts have recently adjusted their price targets, reflecting mixed sentiments. The company declared a quarterly dividend of 15 cents per share.

Portfolio Pulse from Avi Kapoor

September 30, 2024 | 10:56 am

ZION

Morgan Stanley has upgraded Zions Bancorp from Underweight to Equal-Weight, setting a price target of $54.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 10:55 am

ORCL

Bernstein analyst Mark Moerdler maintains an Outperform rating on Oracle and raises the price target from $201 to $202.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 10:55 am

CADE

Morgan Stanley has upgraded Cadence Bank (NYSE:CADE) from Equal-Weight to Overweight, raising the price target from $36 to $39.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 10:52 am

BBIO

HC Wainwright & Co. has reiterated its Buy rating for BridgeBio Pharma, maintaining a price target of $43.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 10:48 am

OVID

HC Wainwright & Co. has reiterated its Buy rating for Ovid Therapeutics, maintaining a price target of $3. This suggests confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 10:42 am

BLFS

HC Wainwright & Co. has initiated coverage on BioLife Solutions (NASDAQ:BLFS) with a Buy rating and set a price target of $29.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 10:39 am

CLDX

Goldman Sachs has initiated coverage on Celldex Therapeutics with a Neutral rating and set a price target of $45.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 10:39 am

LEGN

HC Wainwright & Co. has reiterated its Buy rating on Legend Biotech, maintaining a price target of $73. This suggests confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 10:37 am